Dermira Company Profile (NASDAQ:DERM)

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DERM
  • CUSIP: N/A
  • Web: www.dermira.com
Capitalization:
  • Market Cap: $1.09135 billion
  • Outstanding Shares: 41,591,000
Average Prices:
  • 50 Day Moving Avg: $24.54
  • 200 Day Moving Avg: $29.41
  • 52 Week Range: $21.35 - $38.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.39
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $24.72 million
  • Price / Sales: 44.15
  • Book Value: $8.95 per share
  • Price / Book: 2.93
Profitability:
  • EBIDTA: ($102,210,000.00)
  • Net Margins: -408.50%
  • Return on Equity: -31.66%
  • Return on Assets: -22.59%
Debt:
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 24.43%
  • Quick Ratio: 24.43%
Misc:
  • Average Volume: 418,186 shs.
  • Beta: 0.83
  • Short Ratio: 16.84
 

Frequently Asked Questions for Dermira (NASDAQ:DERM)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira, Inc. (NASDAQ:DERM) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.04. The company earned $1.07 million during the quarter, compared to analyst estimates of $1 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

9 brokerages have issued 1 year price targets for Dermira's shares. Their forecasts range from $40.00 to $48.00. On average, they anticipate Dermira's stock price to reach $44.40 in the next year. View Analyst Ratings for Dermira.

What are analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/17/2017)
  • 2. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:

  • Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
  • Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
  • Luis C. Pena, Co-Founder, Chief Development Officer
  • Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
  • Lori Lyons-Williams, Chief Commercial Officer
  • Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
  • Frederick B. Craves Ph.D., Lead Independent Director
  • Emmanuel Caeymaex, Director
  • David E. Cohen M.D., Independent Director
  • Matthew K. Fust, Independent Director

Who owns Dermira stock?

Dermira's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.45%), NEA Management Company LLC (8.45%), FMR LLC (6.55%), Jennison Associates LLC (6.34%), TimesSquare Capital Management LLC (6.09%) and Vanguard Group Inc. (3.37%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

Who sold Dermira stock? Who is selling Dermira stock?

Dermira's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Balyasny Asset Management LLC, Teachers Advisors LLC, TimesSquare Capital Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC and Century Capital Management LLC. Company insiders that have sold Dermira stock in the last year include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Thomas G Wiggans and William R Ringo. View Insider Buying and Selling for Dermira.

Who bought Dermira stock? Who is buying Dermira stock?

Dermira's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, Jennison Associates LLC, State Street Corp, Tekla Capital Management LLC, JPMorgan Chase & Co., Vanguard Group Inc. and Nexthera Capital LP. View Insider Buying and Selling for Dermira.

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of Dermira stock can currently be purchased for approximately $26.24.


MarketBeat Community Rating for Dermira (NASDAQ DERM)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $44.40 (69.21% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Needham & Company LLCReiterated RatingBuy$46.00HighView Rating Details
9/7/2017MizuhoReiterated RatingBuy$40.00 -> $43.00LowView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
6/22/2017Cantor FitzgeraldInitiated CoverageOverweight$45.00MediumView Rating Details
3/16/2017Raymond James Financial, Inc.Initiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017Citigroup Inc.Initiated CoverageUnderperformHighView Rating Details
3/2/2017GuggenheimReiterated RatingBuy -> Positive$40.00N/AView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Dermira (NASDAQ:DERM)
Earnings by Quarter for Dermira (NASDAQ:DERM)
Earnings History by Quarter for Dermira (NASDAQ DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.89)($0.93)$1.00 million$1.07 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dermira (NASDAQ:DERM)
2017 EPS Consensus Estimate: ($3.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.03)($1.03)($1.03)
Q4 20171($1.29)($1.29)($1.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 97.54%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Thomas G. WiggansCEOSell9,500$27.51$261,345.00View SEC Filing  
9/1/2017David E CohenDirectorSell600$23.56$14,136.00View SEC Filing  
8/28/2017David E CohenDirectorSell600$23.81$14,286.00View SEC Filing  
8/14/2017Fred B CravesDirectorBuy30,000$23.03$690,900.00View SEC Filing  
8/1/2017Thomas G. WiggansCEOSell500$27.58$13,790.00View SEC Filing  
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
Source:
DateHeadline
nasdaq.com logoCommit To Buy Dermira At $17.50, Earn 29.6% Annualized Using Options
www.nasdaq.com - September 22 at 10:14 PM
finance.yahoo.com logoDermira to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:39 PM
americanbankingnews.com logoThomas G. Wiggans Sells 9,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - September 19 at 7:42 PM
finance.yahoo.com logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : September 19, 2017
finance.yahoo.com - September 18 at 10:51 PM
americanbankingnews.com logoDermira, Inc. (DERM) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2017
finance.yahoo.com - September 15 at 6:20 PM
reuters.com logoBRIEF-New CIMZIA findings presented at European Academy Of Dermatology And Venereology (EADV) Congress
www.reuters.com - September 14 at 11:45 PM
finance.yahoo.com logoNew CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
finance.yahoo.com - September 14 at 6:44 PM
finance.yahoo.com logoDermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
finance.yahoo.com - September 14 at 6:44 PM
streetinsider.com logoDermira (DERM) Announces Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
www.streetinsider.com - September 13 at 7:10 PM
finance.yahoo.com logoDermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
finance.yahoo.com - September 13 at 7:10 PM
americanbankingnews.com logoZacks: Analysts Anticipate Dermira, Inc. (DERM) Will Post Earnings of -$1.12 Per Share
www.americanbankingnews.com - September 10 at 8:38 AM
finance.yahoo.com logoIs It The Right Time To Buy Dermira Inc (DERM)?
finance.yahoo.com - September 8 at 11:12 PM
streetinsider.com logoDermira (DERM) Reports New Data on Late-Stage Programs at Leading European Dermatology Congress
www.streetinsider.com - September 8 at 6:11 PM
americanbankingnews.com logoDermira, Inc. (DERM) Earns Buy Rating from Mizuho
www.americanbankingnews.com - September 7 at 10:08 PM
finance.yahoo.com logoDermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress
finance.yahoo.com - September 7 at 5:54 PM
americanbankingnews.com logoDermira, Inc. (DERM) Director David E. Cohen Sells 600 Shares
www.americanbankingnews.com - September 5 at 8:52 PM
americanbankingnews.com logoDermira, Inc. (DERM) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 12:32 PM
americanbankingnews.com logo Analysts Expect Dermira, Inc. (DERM) Will Post Earnings of -$1.12 Per Share
www.americanbankingnews.com - August 22 at 8:26 PM
americanbankingnews.com logoDermira, Inc. (DERM) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 17 at 9:26 PM
americanbankingnews.com logoDermira, Inc. (DERM) Raised to Sell at BidaskClub
www.americanbankingnews.com - August 16 at 11:32 PM
americanbankingnews.com logoDermira, Inc. (DERM) Director Fred B. Craves Buys 30,000 Shares
www.americanbankingnews.com - August 14 at 10:46 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Dermira Inc.
finance.yahoo.com - August 14 at 6:11 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM
finance.yahoo.com logoIs Dermira Inc (NASDAQ:DERM)'s Confidence In Lebrikizumab Warranted?
finance.yahoo.com - August 11 at 12:07 AM
americanbankingnews.com logoLeerink Swann Comments on Dermira, Inc.'s Q3 2017 Earnings (NASDAQ:DERM)
www.americanbankingnews.com - August 10 at 12:04 PM
streetinsider.com logoDermira (DERM) Enters Pact to License Exclusive, Worldwide Rights to Lebrikizumab
www.streetinsider.com - August 9 at 5:58 PM
News IconBRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab
www.businessinsider.com - August 9 at 5:58 PM
americanbankingnews.com logoEquities Analysts Offer Predictions for Dermira, Inc.'s FY2020 Earnings (DERM)
www.americanbankingnews.com - August 9 at 3:02 PM
finance.yahoo.com logoDermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
finance.yahoo.com - August 8 at 5:32 PM
americanbankingnews.com logoDermira, Inc. (DERM) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 12:46 PM
nasdaq.com logoDermira Becomes Oversold (DERM)
www.nasdaq.com - August 7 at 6:12 PM
reuters.com logoBRIEF-Dermira Q2 qtrly ‍net loss per share $0.93
www.reuters.com - August 7 at 6:12 PM
finance.yahoo.com logoDermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 
finance.yahoo.com - August 7 at 6:12 PM
finance.yahoo.com logoDermira reports 2Q loss
finance.yahoo.com - August 7 at 6:12 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) CEO Sells $13,790.00 in Stock
www.americanbankingnews.com - August 2 at 9:38 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 28 at 10:27 PM
finance.yahoo.com logoSuffering from excessive perspiration? Don't sweat it, we...
finance.yahoo.com - July 28 at 7:51 PM
benzinga.com logoUCB and Dermira Announce U.S. and EU Regulatory...
www.benzinga.com - July 25 at 5:49 PM
finance.yahoo.com logoUCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
finance.yahoo.com - July 25 at 3:34 AM
finance.yahoo.com logoETFs with exposure to Dermira, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:32 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017
finance.yahoo.com - July 21 at 7:35 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - July 18 at 1:18 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 12:33 PM
finance.yahoo.com logoETFs with exposure to Dermira, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:45 PM
finance.yahoo.com logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017
finance.yahoo.com - July 12 at 6:28 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 11, 2017
finance.yahoo.com - July 11 at 6:58 PM
americanbankingnews.com logoDermira, Inc. (DERM) Insider Sells $75,000.00 in Stock
www.americanbankingnews.com - July 6 at 8:06 PM
americanbankingnews.com logoInsider Selling: Dermira, Inc. (NASDAQ:DERM) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 3 at 3:22 PM

Social

Chart

Dermira (DERM) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff